Humana stock gains as CenterWell drives Q3 beat (HUM:NYSE)

Humana (HUM) reported Q3 2026 revenue of $41.2B, up 26% YoY, exceeding expectations. The company raised its full-year outlook, driven by its CenterWell segment. Shares rose on the news.

Original reporting
Published Nov 6, 2026, 3:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 3:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Humana stock gains as CenterWell drives Q3 beat (HUM:NYSE) — source image
Decision brief

The 30-second read

$HUMBullishHigh
01

Why it matters

The earnings surprise is likely to attract short-term buying and may set a positive tone for the health insurance sector.

02

Market read

Humana's strong Q3 results provide a clear trading catalyst and may influence related health insurers.

03

What to watch

Potential headwinds from regulatory changes or rising medical cost inflation could temper upside.

Relevance 8/10Novelty 8/10Timing: after-hours reaction

Background

Humana is a large U.S. health insurer; its CenterWell segment contributed to the earnings beat.

Company-level read

Ticker impact

$HUMBullishHigh confidence
Context

Humana reported Q3 2026 revenue of $41.2B, ~26% YoY growth, beating expectations and raising full-year outlook, causing the stock to spike.

Expected impact

upward pressure as the market prices in the earnings beat and raised guidance

Evidence & confidence

The surprise revenue growth and outlook lift investor sentiment, prompting buying.

Market effects

Health insurer earnings beat may boost confidence in the broader health insurance sector.

U.S. market may see modest gains in healthcare stocks.

Limited to U.S. equities; no direct global impact.

Counterpoint

If the beat is already priced in, the stock could face short-term profit taking.

Key entities

  • Humana

    U.S. health insurer (ticker HUM).

  • CenterWell

    Humana's health services segment driving growth.

Related articles

$HUMHighAI 8/10

Humana Raises Profit Floor on Lower Costs

Humana (HUM) raised its 2026 adjusted earnings guidance to at least $9.50 per share from $9.00, citing lower costs. Q3 insurance benefit ratio was 93.7%, better than expected. Shares fell 0.59% in pre-market trading. Humana's Medicare Advantage membership grew 23% this year.

$HUMHighAI 8/10

HUM Q3 FY2026 earnings call

Humana Inc. reported Q3 2026 earnings exceeding expectations, raising full-year adjusted EPS guidance to at least $9.50. The company cited favorable medical cost trends and strong execution. Management highlighted progress in clinical quality, Medicaid expansion, and capital allocation, including a divestiture and a new joint venture. Humana expects 2027 Medicare Advantage membership growth and an 8%-9% medical cost trend, with risks and opportunities outlined.

$HUMHighAI 8/10

[Humana Q3 2026 Earnings Call] Humana Lifts Full-Year EPS Guidance to at Least $9.50 as Medical Cost Trend Lands at Low End of 7%-8% Range

Humana Inc. raised its full-year 2026 adjusted EPS guidance to at least $9.50 per share from $9.00, citing favorable medical cost trends. The company reported strong STARS performance and plans to use excess funds for investments and shareholder returns. Humana also announced balance sheet improvements through divestitures and a new joint venture with BlackRock. Management expects 2027 Medicare Advantage membership growth and higher medical cost trends.

$HUMMed

Humana Lifted Its Profit Forecast As Medical Costs Cooled

Humana raised its profit forecast due to lower medical costs, despite posting an adjusted quarterly loss. The company reported a 93.7% medical cost ratio, which may influence its Medicare Advantage pricing. Humana's individual Medicare Advantage membership grew 23% year-to-date, with a target of 25% growth by 2026 and a pretax margin of at least 3% by 2028.